New vaccines for adolescents

Abstract

@font face { font family: Times ; }p MsoNormal li MsoNormal div MsoNormal { margin: 0cm 0cm 0 0001pt; font size: 12pt; font family: Times New Roman ; }div Section1 { page: Section1; }

Keywords

• -

Ergenlik çağında yeni aşılar

Öz

@font face { font family: Times ; }p MsoNormal li MsoNormal div MsoNormal { margin: 0cm 0cm 0 0001pt; font size: 12pt; font family: Times New Roman ; }div Section1 { page: Section1; }

Anahtar Kelimeler

• Ergen bağışıklaması, Ergen aşılaması, HPV aşısı, suçiçeği aşısı, asellüler boğmaca aşısı, KKK aşısı, meningokok

References

1. Arısoy ES. Ergenlerde aşılama. İçinde: Salman N (ed). Güncel aşılama. İstanbul: Medya tower tanıtım ve yayıncılık hizmetleri, 2008:117-23.
2. CDC. The Advisory Committee on Immunization Practice. Preventing Tetanus, Diphtheria, and Pertussis Among Adolescents: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccines. MMWR Morb Mortal Wkly Rep 2006; 55: 1-34.
3. Committee on Infectious Diseases Recommended childhood immunization Schedule-United States. Pediatrics 2001; 107: 202-4.
4. West DJ, Margolis HS. Prevention of hepatitis B virus infection in the United States: a pediatric perspective. Pediatr Infect Dis J 1992; 11: 866-74. (Abstract)
5. Centers for Disease Control and Prevention, Atlanta Viral Hepatitis Surveillance Report No. 56. 1995; 36: 21-32.
6. Edwards S, Diaz A. Adolescents and Immunization: Tips for the primary care provider. Mount Sinai J Med 2004; 3: 162-5. (Abstract)
7. Gershon AA, LaRussa P, Hardy I, et al. Varicella vaccine: theAmerican experience. J Infect Dis 1992; 166: 63-8. (PDF)
8. Yusuf H, Averhoff F, Smith N, Brink E. Adolescent immunization: rationale, recommendations and implementation strategies. Pediatr Ann 1998; 27: 436-44. (Abstract)

9. Somer A. Meningokok Aşıları. İçinde: Salman N (ed). Güncel aşılama. İstanbul: Medya tower tanıtım ve yayıncılık hizmetleri, 2008:79-95.
10. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007: 297: 813-9. (Abstract) / (Full Text) / (PDF)
11. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 23: 1-24.
12. Bosch FX, Castellsague X, de Sanjose S. HPV and cervical cancer: screening or vaccination? British J Cancer 2008; 98: 15-21. (Abstract) / (Full Text) / (PDF)
13. Bornstein J. Human papillomavirus vaccine: the beginning of the end for cervical cancer. Isr Med Assoc J 2007; 9: 156-8. (Abstract)
14. The Future II Study Group. Quadrivalent vaccine against humanpapillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-27. (Abstract) / (Full Text) / (PDF)
15. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow up from a randomised control trial. Lancet 2006; 367: 1247-55. (Abstract) / (Full Text) / (PDF)
16. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25: 4931-9. (Abstract) / (Full Text) / (PDF)
17. Fedson DS, Musher DM, Eskola J. Pneumococcal vaccine. In: Plotkin SA ed (s). Vaccines. Fourth ed. Philadelphia: WB Saunders, 1999: 553-607.
18. American Academy of Pediatrics. Pneumococcal infections. In: Pickering LK ed (s). Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village IL: American Academy of Pediatrics; 2006: 525-37.